May 5, 2010 (FinancialWire) — PharmAthene, Inc. (AMEX: PIP), a biodefense firm developing medical countermeasures against biological and chemical threats, said that the company's board of directors has appointed Eric I. Richman to the position of interim chief executive officer, replacing David Wright, who has submitted his resignation.  

Richman joined PharmAthene in October 2003, bringing experience in the development and commercialization of novel biotechnology-based therapeutics. As a member of the founding team at MedImmune, he was responsible for the U.S. launch of MedImmune's first commercial product, CytoGam, and was on the launch teams for its other products including the international launch of Synagis. Prior to joining MedImmune, he began his career at HealthCare Ventures, a life-sciences focused venture capital firm.

Richman served on the board of Lev Pharmaceuticals and currently serves on the Board of ADMA Biologics and American Bank.

Maryland-based PharmAthene was formed to meet the needs of the United States and its allies by developing and commercializing medical countermeasures against biological and chemical weapons. PharmAthene's lead product development programs include SparVax – a second generation recombinant protective antigen anthrax vaccine.

The firm is also working on a third generation rPA anthrax vaccine,

Valortim – a fully human monoclonal antibody for the prevention and treatment of anthrax infection. The firm’s Protexia is a novel bioscavenger for the prevention and treatment of morbidity and mortality associated with exposure to chemical nerve agents.

Real-time, streaming research for companies and funds mentioned in FinancialWire(tm) news is available via the Investrend Research Syndicate, courtesy of Stock Smart (at http://investrend.stocksmart.com/ss/html/hpcompany.html).

FinancialWire(tm) is committed to serving the financial community through true journalism and providing relevant resources to investors. Standards-based, independent equity research on numerous public companies is available through the Investrend Research Syndicate (http://www.investrend.com/reports) written by FIRST Research Consortium (http://www.investrend.com/FIRST) member-providers. Free annual reports and company filings for companies mentioned in the news are available through the Investrend Information Syndicate (at http://investrend.ar.wilink.com/?level=279). FinancialWire(tm), in cooperation with the Investrend Broadcast Syndicate, also provides complete, daily conference call and webcast schedules as a service to shareholders and investors via the FirstAlert(tm) Network’s “FirstAlert(tm) Daily” (at http://www.financialwire.net/news-alerts/).

FinancialWire(tm) is a fully independent, proprietary news wire service. FinancialWire(tm) is not a press release service, and receives no compensation for its news, opinions or distributions. Further disclosure is at the FinancialWire(tm) website at http://www.financialwire.net/disclosures.php and http://www.financialwire.net/2010/04/23/safe-harbor/). Additional resources for investors are also accessible via the FinancialWire(tm) website (at http://www.financialwire.net/2010/04/23/investor-resources/). Contact FinancialWire(tm) directly via inquiries@financialwire.net.

[hlmsmlh] [scrtytrcs] [biomedphrm] [clvloy]

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.